2026 BioPharma eMarketing Summit

Somewhere in the last eighteen months, the content moved faster than the conscience. AI-generated health content is now being published, shared, and acted on at a scale no medical reviewer, no compliance team, and no platform algorithm was built to handle — and the biopharma industry is still debating its AI content policy while patients make treatment decisions based on posts no human wrote and no expert verified. This session doesn't ask whether AI belongs in healthcare influence. That debate is over. It asks the question the room has been avoiding: now that the machine can produce medically plausible content at infinite scale, who exactly is responsible when it's wrong? Challenging the comfortable assumption that good intent and strong guidelines are enough, this talk maps the gap between the speed of AI content generation and the speed of human verification — and names it for what it is: the most consequential trust problem the industry has ever created for itself. Attendees will leave not with a policy checklist, but with a sharper sense of urgency — and a clear-eyed view of what it will actually take to close the gap before a patient pays the price.

Few people have sat in both seats. Robert Britting Jr. has — as a senior pharma executive and as a Mayor. And what he's seen from both sides of the table might surprise you. In this candid, cross-sector keynote, Robert draws unexpected parallels between governing a community and marketing a medicine — exploring how pharma can borrow from government's playbook on public trust, stakeholder communication, and community-centered decision making. And what government could desperately learn from pharma's discipline, speed, and data-driven culture. Two worlds. One powerful lens. And lessons neither sector has been willing to say out loud — until now.

Pharma has spent a decade optimizing channels, but more data hasn't brought us closer to patients or HCPs — it's abstracted them. This session explores how generative and predictive AI can transform insights from static snapshots into continuous, contextual conversations — and shares a practical capability framework for making it real. Attendees will leave with a sharper lens on where their own insights are still episodic, and a clear-eyed view of how to balance intelligent systems with empathy, trust, and human connections.

AI is advancing faster than any technology in history, reshaping how we think, work, and create. For pharma marketers, the real question is not whether AI will take our jobs but how we’ll redefine them. This session explores the growing gap between exponential AI progress and the slower human pace of adoption. Attendees will learn how to treat AI as a creative partner, build new collaboration skills, and stay indispensable in the age of AI.Key takeaways:• Exponential AI growth is transforming marketing, creativity, and work itself.• Pharma marketing will evolve from executing campaigns to orchestrating systems that learn, adapt, and co-create.• The best marketers experiment relentlessly with AI to build comfort and skill, and treat AI as a thinking partner, not a tool.• Human insight, judgment, and authenticity will remain essential to brand trust and storytelling.

---

1. Omnichannel has been a buzzword in pharma for nearly a decade — yet most companies still struggle to execute it consistently. What's the real reason the industry keeps falling short, and what's finally changed in 2026 that makes excellence actually achievable?

---

2. AI-powered orchestration promises hyper-personalized patient engagement at scale — but pharma operates under some of the strictest compliance and privacy constraints in any industry. Where does the tension between personalization and regulatory risk actually break down in practice, and how are leading companies navigating it?

---

3. You mentioned four must-have capabilities for a high-impact patient omnichannel strategy. Most companies will claim they already have some version of these — so what separates the organizations that are truly executing from those that are just checking boxes?

---

4. We talk a lot about reaching patients, but omnichannel success ultimately depends on changing behavior — whether that's adherence, treatment-seeking, or HCP conversations. Where in the patient journey are companies seeing the biggest ROI from omnichannel investment right now, and where is the industry still leaving value on the table?

---

5. The case studies from top pharmaceutical companies are compelling — but large pharma has resources, technology infrastructure, and data that mid-size and specialty companies simply don't have. What does omnichannel excellence actually look like for an organization that doesn't have an unlimited budget and a 50-person digital team?

---

6. If you could eliminate one widely-held belief about omnichannel strategy in pharma — something the industry keeps getting wrong — what would it be, and what should replace it?

Today's patients arrive at appointments armed with research, opinions, and alternatives. This talk reframes the empowered patient not as a challenge but as your greatest marketing opportunity — and shows how synchronizing brand messaging between patients and providers creates a shared knowledge environment that accelerates trust and treatment decisions.

THE BEGINNER'S ADVANTAGE
The pharmaceutical industry has a habit of inducting new marketers into its own logic before they can question it. Kiana got here differently — with enough battle scars from tech and telecom to know when a "that's how we do it here" is wisdom, and when it's just inertia. A candid session on the assumptions baked into pharma marketing that the industry has stopped noticing — and what it might look like to challenge them.

Imagine a closing session designed across the two-day event. Your feedback, your insights, your gaps, your inspirations – all captured to shape the final session and participants.



This is an audience curated, high‑energy wrap‑up, not another heavy slide deck. We’ll crowd‑source the top themes and questions from today and invite a cross‑functional panel of audience members, speakers, and exhibitors to respond in real time so you are heard and leave with your answers, takeaways, and opportunities.